HDAC-IN-4

CAS No. 934828-12-3

HDAC-IN-4( AZD 9468 )

Catalog No. M16687 CAS No. 934828-12-3

A histone deacetylase (HDAC) inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 113 In Stock
10MG 178 In Stock
25MG 365 In Stock
50MG 537 In Stock
100MG 767 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    HDAC-IN-4
  • Note
    Research use only, not for human use.
  • Brief Description
    A histone deacetylase (HDAC) inhibitor.
  • Description
    A histone deacetylase (HDAC) inhibitor, extracted from patent WO/2007045844 A1.(In Vitro):Zabadinostat has been tested in vitro in colon, lung, non-Hodgkin lymphoma, and myeloma cell lines with IC50s ranged from 0.2 to 15 μM.(In Vivo):Zabadinostat substantially reduces tumor size in murine xenograft lung (A549a) and colon (HT29) models at a dose of 50 mg/kg. Tumor reductions are found to be associated with increased histone acetylation and decreased HDAC enzyme activity.For Zabadinostat, after oral dosing in murine and canine models, peak plasma concentrations (Cmax) are reached 1 to 2 hours after the dose and terminal half‐lives are 6 hours and 8 hours, respectively. After murine oral [14C]-Zabadinostat at a dose of 1.6 mg/kg (4 μmol/kg), tissue radioactivity peaked 3 to 6 hours after the dose and declined slowly thereafter with Zabadinostat‐related material still present in tissue 21 days after the dose.
  • In Vitro
    Zabadinostat has been tested in vitro in colon, lung, non-Hodgkin lymphoma, and myeloma cell lines with IC50s ranged from 0.2 to 15 μM.
  • In Vivo
    Zabadinostat substantially reduces tumor size in murine xenograft lung (A549a) and colon (HT29) models at a dose of 50 mg/kg. Tumor reductions are found to be associated with increased histone acetylation and decreased HDAC enzyme activity.For Zabadinostat, after oral dosing in murine and canine models, peak plasma concentrations (Cmax) are reached 1 to 2 hours after the dose and terminal half‐lives are 6 hours and 8 hours, respectively. After murine oral [14C]-Zabadinostat at a dose of 1.6 mg/kg (4 μmol/kg), tissue radioactivity peaked 3 to 6 hours after the dose and declined slowly thereafter with Zabadinostat‐related material still present in tissue 21 days after the dose.
  • Synonyms
    AZD 9468
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    HDAC
  • Recptor
    HDAC
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    934828-12-3
  • Formula Weight
    403.52
  • Molecular Formula
    C24H29N5O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 31 mg/mL
  • SMILES
    O=C(NC1=CC=CC=C1N)C2=CC=C(C3CCN(CC4=CN(C)N=C4C)CC3)C=C2
  • Chemical Name
    Benzamide, N-(2-aminophenyl)-4-[1-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]-4-piperidinyl]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. PCT Int. Appl. (2007), WO 2007045844 A1 20070426.
molnova catalog
related products
  • BRD 8430

    BRD 8430 is a potent, selective class I HDAC inhibitor (HDAC1>2 >3) with IC50 of 69 nM/560/1300 nM for HDAC1/2/3, respectively.

  • Tubacin

    Tubacin is a potent, selective inhibitor of class II histone deacetylase 6 (HDAC6) with IC50 of 4 nM.

  • CUDC-101

    A potent, multi-targeted HDAC, EGFR and HER2 inhibitor with IC50 of 4.4, 2.4, and 15.7 nM, respectively.